New hope for tough prostate cancer? drug trial targets resistant tumors

NCT ID NCT07226713

Not yet recruiting Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests an oral drug called pacritinib in 32 men with metastatic castrate-resistant prostate cancer that has worsened after standard treatments. The drug is taken twice daily, and the main goal is to see if it can delay cancer growth for at least six months. Participants must have a biopsy showing a specific protein activation (STAT5) to be eligible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pacritinib (an oral drug taken twice daily)
What this could lead to: If successful, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial with only 32 participants and no comparison group, so results may not be definitive. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.